Advertisement

PentaVision

Optometric Management

Article

LEADING OFF: Also Notable

Optometric Management January 1, 2023 Vol 58, Issue January/February 2023 Page(s): 18
  • According to a survey from the American Optometric Association Research & Information Committee, 69% of optometrists report providing myopia management services in their practices, and three out of four say they consider myopia to be a disease in need of treatment. For more information from the survey, go to bit.ly/AOAMyopiaSurvey .
  • Alcon and the World Council of Optometry launched dryeye.worldcouncilofoptometry.info , which features on-demand educational webinars and in-practice tools, such as clinical studies and white papers, among other professional development resources. The first on-demand Dry Eye Spotlight webinar, “Dry Eye Disease Mitigation,” is now available. Another Alcon and WCO-sponsored dry eye webinar, “Dry Eye Spotlight 2: Measurement,” will be available Jan. 31. To register for the Jan. 31 webinar, visit https://oaandgap.eventsair.com/wcodydmeasurement/reg/Site/Register .
  • The Contact Lens Institute released the on-demand version of “See Tomorrow,” an online learning event. Specifically, “Remarkable Resilience: Eye Care Insights for a Challenging Economy” is a 60-minute webinar that centers on new research that uncovered U.S. consumer beliefs and behaviors about eye care choices, discretionary spending, and contact lens habits. It is available for free on CLI’s YouTube channel.
  • CooperVision and The World Council of Optometry have issued a Myopia Management Standard of Care Pledge challenge. More than 35 global eye care organizations and 25,000 practitioners have so far pledged to adopt this myopia management as the standard of care. Learn more about the pledge at bit.ly/WCOMyopiaPledge .
  • Eyenovia, Inc. announced the FDA accepted the company’s New Drug Application for its MydCombi ophthalmic spray. MydCombi is a drug-device combination of tropicamide and phenylephrine for in-office pupil dilation, administered via Eyenovia’s investigational Optejet drug-delivery technology. The FDA assigned the NDA a standard review with a Prescription Drug User Fee Act target action date of May 8, 2023. In other news, Eyenovia Inc. promoted Bren Kern to COO and corporate vice president, effective Jan. 1. 2023. He currently serves as senior vice president of manufacturing and operations.
  • MaximEyes developers, First Insight Corp., received the Office of the National Coordinator for Health Information Technology (ONC Health IT) 2015 Edition Cures Update Certification. MaximEyes.com EHR (version 1.1 and higher) and MaximEyes EHR (version 3.0 and higher) are ONC 2015 Edition Cures Update and Fast Healthcare Interoperability Resources (FHIR) compliant and have been certified by Drummond Group LLC, an ONC-ACB (Authorized Certification Body), per the applicable certification criteria adopted by the Secretary of Health and Human Services.
  • Harrow has acquired exclusive U.S. commercial rights to five Novartis products: Ilevro (nepafenac ophthalmic suspension) 0.3%; Nevnac (nepafenac ophthalmic suspension) 0.1%; Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5; Maxidex (dexamethasone ophthalmic suspension) 0.1%; and Triesense (triamcinolone acetonide injectable suspension) 40 mg/ml. Harrow has also launched https://atropine.com , an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com prescriptions will be dispensed through Harrow subsidiary ImprimisRx.
  • Kala Pharmaceuticals, Inc. submitted an investigational new drug (IND) application to the FDA for its KPI-012, a treatment for persistent corneal epithelial defect (PCED). Subject to the FDA’s acceptance of the IND, Kala says it remains on-track to start a Phase 2b clinical trial of KPI-012 for PCED in the fourth quarter of 2022. Topline safety and efficacy data from the trial is expected in the first quarter of 2024.
  • Ocuphire Pharma, Inc. announced the submission of a new drug application (NDA) to the FDA for its phentolamine ophthalmic solution 0.75% (Nyxol) for the reversal of pharmacologically induced mydriasis produced by adrenergic agonist (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents, or a combination thereof. The NDA is supported by positive results from a clinical program comprised of over 600 subjects.
  • TearCare released independent data that addresses how long a single treatment of lasts. Dry eye patients throughout the study, which examined 78 people, exhibited improved dry eye signs and symptoms for more than 12 months, and in some cases up to 18 months, post treatment. Additionally, patients experienced a 44% decrease in dry eye symptoms from baseline to week eight, and meibomian gland function was found to improve by 63%. The data was presented at the 2022 American Academy of Optometry meeting.
  • According to the 2022 Transitions Optical Workplace Wellness survey, a total of 88% of employees report they are likely to purchase premium lens options if recommended by an eye care professional. Further, 86% of employees say they are likely to spend more than their insurance allowance for a new pair of glasses, and 96% of the employees report they are willing to pay above what their insurance fully covers for premium lens options, such as UV protection, blue light protection, and photochromic lenses.
  • According to The Vision Council’s “Focused inSights: Online vs. In-Person Buyers 2022” report, online buyers have made glasses purchases more recently, intend to do so again sooner, and are more likely to buy multiple pairs vs. in-person buyers. The report is based on The Vision Council’s monthly consumer survey and a survey focused on how consumers make decisions about their eyewear and eye care. For more information go to bit.ly/VisCouncilResearch . OM

What to Read Next